ChemoCentryx Inc  

(Public, NASDAQ:CCXI)   Watch this stock  
Find more results for Susan Lucas
6.40
-0.18 (-2.74%)
Real-time:   10:00AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.38 - 6.51
52 week 4.06 - 9.46
Open 6.43
Vol / Avg. 4,500.00/94,715.00
Mkt cap 282.07M
P/E     -
Div/yield     -
EPS -1.09
Shares 44.07M
Beta 0.47
Inst. own 70%
Nov 3, 2015
Q3 2015 ChemoCentryx Inc Earnings Release (Estimated) Add to calendar
Sep 9, 2015
ChemoCentryx Inc at Rodman & Renshaw Global Investment Conference - 12:05PM EDT - Add to calendar
Aug 6, 2015
Q2 2015 ChemoCentryx Inc Earnings Call - Webcast
Aug 6, 2015
Q2 2015 ChemoCentryx Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -47.58% -34.84%
Return on average equity -50.91% -36.96%
Employees 58 -
CDP Score - -

Address

850 Maude Ave
MOUNTAIN VIEW, CA 94043-4022
United States - Map
+1-650-2102900 (Phone)
+1-650-2102910 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. The Company's product portfolio includes CCX140, CCX872, CCX168, Vercirnon (Traficet-EN or CCX282) and CCX507.

Officers and directors

Thomas J. Schall Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Susan M. Kanaya Chief Financial Officer, Senior Vice President - Finance, Secretary
Age: 52
Bio & Compensation  - Reuters
Petrus J. Bekker M.D., Ph.D. Senior Vice President - Clinical and Medical Affairs
Age: 54
Bio & Compensation  - Reuters
Israel F. Charo M.D., Ph.D. Senior Vice President - Research
Age: 65
Bio & Compensation  - Reuters
Markus J. Cappel Ph.D. Chief Business Officer, Treasurer
Age: 54
Bio & Compensation  - Reuters
Roger C. Lucas Ph.D. Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Thomas A. Edwards JD, Independent Director
Age: 56
Bio & Compensation  - Reuters
Joseph M. Feczko M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Geoffrey M. Parker Independent Director
Age: 50
Bio & Compensation  - Reuters
James L. Tyree Independent Director
Age: 62
Bio & Compensation  - Reuters